Novartis Ag (NVSEF) Net Income (2009 - 2025)
Novartis Ag's (NVSEF) quarterly Net Income came in at $4.5 billion in Q2 2025, up 17.96% year-on-year from $3.8 billion in Q2 2024, and down 34.99% quarter-over-quarter from $7.0 billion in Q4 2024.
Novartis Ag (NVSEF) Net Income (2009 - 2025) Analysis & Trends
Novartis Ag has disclosed Net Income across 15 years of filings, most recently posting $4.5 billion for Q2 2025.
- Net Income for Q2 2025 came in at $4.5 billion, up 17.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 billion (down 58.09% YoY), and the FY2025 annual result was $14.0 billion, up 16.99% from the prior year.
- Net Income came in at $4.5 billion for Q2 2025 at Novartis Ag, down from $7.0 billion in the prior quarter.
- In the past five years, Net Income ranged from a high of $7.0 billion in Q4 2024 to a low of $46.0 million in Q2 2023.
- The 5-year median for Net Income is $595.0 million (2022), against an average of $2.0 billion.
- Across the five-year window, Net Income sank 97.75% in 2023 and soared 8250.0% in 2024, its largest moves.
- Novartis Ag's Net Income stood at $6.0 billion in 2021, then plunged by 97.46% to $151.0 million in 2022, then gained by 25.83% to $190.0 million in 2023, then soared by 3568.42% to $7.0 billion in 2024, then slumped by 34.99% to $4.5 billion in 2025.
- The last three Net Income figures came in at $4.5 billion (Q2 2025), $7.0 billion (Q4 2024), and $3.8 billion (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 3.30 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Novartis Ag | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 4.53 Bn |
| Dec 31, 2024 | 6.97 Bn |
| Jun 30, 2024 | 3.84 Bn |
| Dec 31, 2023 | 190.00 Mn |
| Sep 30, 2023 | 250.00 Mn |
| Jun 30, 2023 | 46.00 Mn |
| Mar 31, 2023 | 144.00 Mn |
| Dec 31, 2022 | 151.00 Mn |
| Sep 30, 2022 | 245.00 Mn |
| Jun 30, 2022 | 2.04 Bn |
| Mar 31, 2022 | 595.00 Mn |
| Dec 31, 2021 | 5.96 Bn |
| Sep 30, 2021 | 642.00 Mn |
| Jun 30, 2021 | 3.51 Bn |
| Mar 31, 2021 | 514.00 Mn |
| Dec 31, 2020 | 4.91 Bn |
| Sep 30, 2020 | 604.00 Mn |
| Jun 30, 2020 | 2.29 Bn |
| Mar 31, 2020 | 194.00 Mn |
| Jun 30, 2019 | 4.69 Bn |